The most recent trading session ended with Viking Therapeutics, Inc. (VKTX) standing at $29.28, reflecting a +1.14% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily gain of 1.77%. Elsewhere, the Dow saw an upswing of 1.42%, while the tech-heavy Nasdaq appreciated by 2.28%.

The the stock of company has fallen by 15.03% in the past month, lagging the Medical sector's loss of 1.17% and the S&P 500's loss of 5.73%.

Analysts and investors alike will be keeping a close eye on the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. In that report, analysts expect Viking Therapeutics, Inc. to post earnings of -$0.34 per share. This would mark a year-over-year decline of 30.77%.

Any recent changes to analyst estimates for Viking Therapeutics, Inc. should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, Viking Therapeutics, Inc. is carrying a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 74, finds itself in the top 30% echelons of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research